Skip to main content

Metamark, Definiens Partner on Cancer Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics and Definiens today announced that they are collaborating on the development and commercialization of a multiplex platform that will run prognostic and predictive assays for early-stage cancers.

The collaboration will combine Metamark's multiplex protein detection platform with image analysis technology that the Cambridge, Mass.-based firm will jointly develop with Munich, Germany-based Definiens. The firms said that Metamark's quantitative diagnostic approach can "identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor."

Financial and other terms of the alliance were not disclosed.

"The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine," Thomas Colarusso, VP of sales and operations for Definiens, said in a statement. "We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.